Investors apparently aren't too impressed with Cubist Pharmaceuticals' (CBST -2.6%) new...

|By:, SA News Editor

Investors apparently aren't too impressed with Cubist Pharmaceuticals' (CBST -2.6%) new five-year strategic plan. CBST says it expects to boost global revenue to $2B annually, have four product candidates in late-stage clinical trials, and generate $700M in non-GAAP annual adjusted operating income.